These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 22703527

  • 1. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY.
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
    Gong Y, Song L, Ou L, Lu YY, Huang X, Zeng Q.
    Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung KH, Lee JC, Lee J, Cho IK, Kim J, Jang W, Yoo BC, Hwang JH.
    Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
    [Abstract] [Full Text] [Related]

  • 11. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
    Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Nomoto S, Kodera Y.
    Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
    [Abstract] [Full Text] [Related]

  • 12. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
    Xu P, Wang X, Qian J, Li Z, Yao J, Xu A.
    Medicine (Baltimore); 2021 Feb 12; 100(6):e24651. PubMed ID: 33578593
    [Abstract] [Full Text] [Related]

  • 13. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.
    J Natl Cancer Inst; 2017 Apr 01; 109(4):. PubMed ID: 28376157
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J.
    Cancer Biomark; 2018 Feb 14; 21(3):505-511. PubMed ID: 29171983
    [Abstract] [Full Text] [Related]

  • 16. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
    Suzuki S, Shimoda M, Shimazaki J, Maruyama T, Oshiro Y, Nishida K, Sahara Y, Nagakawa Y, Tsuchida A.
    Eur Surg Res; 2018 Feb 14; 59(5-6):329-338. PubMed ID: 30453288
    [Abstract] [Full Text] [Related]

  • 17. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ.
    Pancreas; 2013 Mar 14; 42(2):193-7. PubMed ID: 23407481
    [Abstract] [Full Text] [Related]

  • 18. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
    Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W.
    BMC Cancer; 2014 Aug 08; 14():578. PubMed ID: 25106741
    [Abstract] [Full Text] [Related]

  • 19. Serum matrix metalloproteinase-7, Syndecan-1, and CA 19-9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma.
    Yablecovitch D, Nadler M, Ben-Horin S, Picard O, Yavzori M, Fudim E, Duchan MT, Sakhnini E, Lang A, Lahav M, Saker T, Neuman S, Selinger L, Freitz B, Dvir R, Raitses-Gurevich M, Golan T, Levy I, Laish I.
    Cancer Med; 2024 Sep 08; 13(17):e70144. PubMed ID: 39263943
    [Abstract] [Full Text] [Related]

  • 20. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY, Dong YP, Sun X, Sui X, Zhu H, Zhao YQ, Zhang YY, Mason C, Zhu Q, Han SX.
    Cancer Med; 2018 Nov 08; 7(11):5525-5533. PubMed ID: 30358133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.